Bluejay Diagnostics, Inc.
BJDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | 19.6% | – |
| R&D Expenses | $3 | $6 | $4 | $1 |
| G&A Expenses | $4 | $4 | $5 | $2 |
| SG&A Expenses | $4 | $5 | $5 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $7 | $10 | $9 | $3 |
| Operating Income | -$7 | -$10 | -$9 | -$3 |
| % Margin | – | – | -3,741.5% | – |
| Other Income/Exp. Net | -$1 | $0 | $0 | -$0 |
| Pre-Tax Income | -$8 | -$10 | -$9 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$10 | -$9 | -$4 |
| % Margin | – | – | -3,733.1% | – |
| EPS | -42.08 | -72.62 | -73.22 | -29.67 |
| % Growth | 42.1% | 0.8% | -146.8% | – |
| EPS Diluted | -42.08 | -72.62 | -73.22 | -29.67 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$7 | -$9 | -$9 | -$3 |
| % Margin | – | – | -3,618.5% | – |